[HTML][HTML] Recent advances in therapeutic strategies for triple-negative breast cancer
Y Li, H Zhang, Y Merkher, L Chen, N Liu… - Journal of hematology & …, 2022 - Springer
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …
Deciphering breast cancer: from biology to the clinic
E Nolan, GJ Lindeman, JE Visvader - Cell, 2023 - cell.com
Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
[HTML][HTML] Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer
Background In an interim analysis of this phase 3 trial, the addition of pembrolizumab to
chemotherapy resulted in longer progression-free survival than chemotherapy alone among …
chemotherapy resulted in longer progression-free survival than chemotherapy alone among …
Event-free survival with pembrolizumab in early triple-negative breast cancer
Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …
significantly higher percentage of patients with early triple-negative breast cancer having a …
Treatment landscape of triple-negative breast cancer—expanded options, evolving needs
G Bianchini, C De Angelis, L Licata… - Nature reviews Clinical …, 2022 - nature.com
Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
[HTML][HTML] Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy
Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …
[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …
HJ Burstein, G Curigliano, B Thürlimann, WP Weber… - Annals of oncology, 2021 - Elsevier
The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …
The next decade of immune checkpoint therapy
P Sharma, BA Siddiqui, S Anandhan, SS Yadav… - Cancer discovery, 2021 - AACR
Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline
LA Korde, MR Somerfield, LA Carey… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …